Alzheimer Disease Cerebrospinal Fluid Biomarkers in a Tertiary Neurology Practice
Mayo Clinic Proceedings · 2024-08 · 99 (8) · 1284-1296
DOI: 10.1016/j.mayocp.2023.12.024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Mayo Clinic Proceedings, 2024-08. Verfasst von Wentao Li und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Mayo Clinic, Rochester, MN; Department of Neurology, Kaiser Permanente South Sacramento, Sacramento, CA. Hauptthemen laut MEDLINE: Alzheimer Disease, Biomarkers, Amyloid beta-Peptides, tau Proteins. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NINDS NIH HHS, National Institute on Aging.
Themen: Demenz
Abstract (Originalsprache)
OBJECTIVE: To evaluate the performance of Alzheimer disease (AD) cerebrospinal fluid (CSF) biomarkers in a tertiary neurology clinic setting with high frequency of non-AD cases, including normal pressure hydrocephalus (NPH). METHODS: There were 534 patients who underwent AD CSF biomarkers (Roche Elecsys Aβ42, p-Tau181, total-Tau) from April 1, 2020, through April 23, 2021. A behavioral neurologist blinded to CSF results assigned a clinical diagnosis retrospectively on the basis of consensus criteria, and a neuroradiologist blinded to the diagnosis and CSF studies graded brain magnetic resonance images for indicators of CSF dynamics disorders. Associations between biomarkers, diagnoses, and imaging were assessed by χ2, analysis of covariance, and linear regression methods. RESULTS: Median age at time of testing was 67 years (range, 19 to 96 years), median symptom duration was 2 years (range, 0.4 to 28 years), and median Short Test of Mental Status score was 30 (range, 0 to 38). Clinical diagnoses significantly correlated with different CSF biomarker values (χ2=208.3; P=10e-4). p-Tau181/Aβ42 ratios above 0.023 positively correlated with Alzheimer dementia (more than individual measures). This ratio also had the best performance for differentiating Alzheimer dementia from NPH (area under the curve, 0.869). Imaging markers supportive of CSF dynamics disorders correlated with low Aβ42, p-Tau181, and total-Tau. CONCLUSION: In a heterogeneous clinical population, abnormal p-Tau181/Aβ42 ratios (>0.023) have the strongest association with Alzheimer dementia and probably represent a comorbid AD pathologic component in persons clearly matching non-AD neurodegenerative syndromes. Altered CSF dynamics were associated with lower concentrations of AD CSF biomarkers regardless of clinical diagnosis, but the ratio compensates for these changes. In the appropriate clinical setting, an isolated abnormal Aβ42 should prompt consideration of NPH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Mayo Clinic, Rochester, MN; Department of Neurology, Kaiser Permanente South Sacramento, Sacramento, CA.
- Department of Neurology, Mayo Clinic, Rochester, MN.
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
- Department of Radiology, Mayo Clinic, Rochester, MN.
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN.
- Department of Neurology, Mayo Clinic, Jacksonville, FL.
Förderung
- NIA NIH HHS
- NINDS NIH HHS
- National Institute on Aging
- Eli Lilly and Company
- National Institutes of Health
- Alzheimer's Association
Zitieren
APA
Li, W., Petersen, R. C., Algeciras-Schimnich, A., Cogswell, P. M., Bornhorst, J. A., Kremers, W. K., Boeve, B. F., Jones, D. T., Botha, H., Ramanan, V. K., Knopman, D. S., Savica, R., Josephs, K. A., Cliatt-Brown, C., Andersen, E., Day, G. S., Graff-Radford, N. R., Ertekin-Taner, N., Lachner, C., …, & Graff-Radford, J. (2024). Alzheimer Disease Cerebrospinal Fluid Biomarkers in a Tertiary Neurology Practice. Mayo Clinic Proceedings, 99(8), 1284-1296. https://doi.org/10.1016/j.mayocp.2023.12.024
Vancouver
Li W, Petersen RC, Algeciras-Schimnich A, Cogswell PM, Bornhorst JA, Kremers WK, et al. Alzheimer Disease Cerebrospinal Fluid Biomarkers in a Tertiary Neurology Practice. Mayo Clinic Proceedings. 2024;99(8):1284-1296. doi:10.1016/j.mayocp.2023.12.024
BibTeX
@article{Li2024,
author = {Li, Wentao and Petersen, Ronald C and Algeciras-Schimnich, Alicia and Cogswell, Petrice M and Bornhorst, Joshua A and Kremers, Walter K and Boeve, Bradley F and Jones, David T and Botha, Hugo and Ramanan, Vijay K and Knopman, David S and Savica, Rodolfo and Josephs, Keith A and Cliatt-Brown, Christine and Andersen, Emerlee and Day, Gregory S and Graff-Radford, Neill R and Ertekin-Taner, Nilüfer and Lachner, Christian and Wicklund, Meredith and van Harten, Argonde and Woodruff, Bryan K and Caselli, Richard J and Graff-Radford, Jonathan},
title = {Alzheimer Disease Cerebrospinal Fluid Biomarkers in a Tertiary Neurology Practice},
journal = {Mayo Clinic Proceedings},
year = {2024},
volume = {99},
number = {8},
pages = {1284--1296},
doi = {10.1016/j.mayocp.2023.12.024}
}
EUVIMED